Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Fürstenau, M."" wg kryterium: Autor


Wyświetlanie 1-51 z 51
Tytuł :
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia
Autorzy :
Fürstenau, M.
Bahlo, J.
Fink, A. M.
Lange, E.
Dreger, P.
Dreyling, M.
Hess, G.
Ritgen, M.
Kneba, M.
Döhner, H.
Stilgenbauer, S.Aff7, Aff8
Wendtner, C. M.
Goede, V.
Fischer, K.
Böttcher, S.Aff6, Aff11
Hallek, M.Aff1, Aff12
Eichhorst, B.
Pokaż więcej
Źródło :
Leukemia. 34(3):924-928
Czasopismo naukowe
Tytuł :
BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG.
Autorzy :
Cramer, P
Fürstenau, M
Robrecht, S
Giza, A
Fink, A. M
Fischer, K
Langerbeins, P
Al Sawaf, O
Tausch, E
Schneider, C
Schetelig, J
Dreger, P
Böttcher, S
Kreuzer, K. A
Schilhabel, A
Brüggemann, M
Kneba, M
Wendtner, C. M
Stilgenbauer, S
Eichhorst, B
Pokaż więcej
Źródło :
Hematological Oncology; Jun2021 Supplement S2, Vol. 39, p1-3, 3p
Czasopismo naukowe
Tytuł :
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL.
Autorzy :
Langerbeins, P.
Bahlo, J.
Rhein, C.
Gerwin, H.
Cramer, P.
Fürstenau, M.
Al‐Sawaf, O.
Tresckow, J.
Fink, A.M.
Kreuzer, K.
Vehling‐Kaiser, U.
Tausch, E.
Müller, L.
Eckart, M.
Schlag, R.
Freier, W.
Gaska, T.
Balser, C.
Reiser, M.
Stauch, M.
Pokaż więcej
Temat :
PLACEBOS
PROGRESSION-free survival
Źródło :
Hematological Oncology; Jun2019 Supplement S2, Vol. 37, p38-40, 3p
Czasopismo naukowe
Tytuł :
Durable Remissions Following Combined Targeted Therapy in Patients with CLL Harboring TP53 Deletions and/or Mutations.
Autorzy :
Cramer P; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
Tausch E; Ulm University, Ulm, Germany.
von Tresckow J; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany.
Giza A; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.
Robrecht S; University Hospital of Cologne, Köln, Germany.
Schneider C; Ulm University, Ulm, Germany.
Fürstenau M; University Hospital Cologne, Cologne, Germany.
Langerbeins P; University Hospital, Cologne, Germany.
Al-Sawaf O; University Hospital of Cologne, Cologne, Germany.
Pelzer BW; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.
Fink AM; University Hospital of Cologne, Cologne, Germany.
Fischer K; University Hospital Cologne, Cologne, Germany.
Wendtner CM; Hospital Munich-Schwabing, München, Germany.
Eichhorst B; University of Cologne, Cologne, Germany.
Kneba M; University Hospital Schleswig Holstein Campus Kiel, Kiel, Germany.
Stilgenbauer S; University of Ulm, Ulm, Germany.
Hallek M; University Hospital, Cologne, Germany.
Pokaż więcej
Źródło :
Blood [Blood] 2021 Jun 04. Date of Electronic Publication: 2021 Jun 04.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Autorzy :
Fürstenau M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Schilhabel A; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Weiss J; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Robrecht S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Eckert R; Onkologische Schwerpunktpraxis Esslingen, Esslingen, Germany.
de la Serna J; Servicio de Hematología, Hospital Universitario 12 de Octubre, Madrid, Spain.
Crespo M; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
Coscia M; University Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Vitale C; University Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Böttcher S; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.; Medical Clinic III, Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
Weppner G; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Ritgen M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Stilgenbauer S; Department of Internal Medicine III, University of Ulm, Ulm, Germany.; Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany; and.
Tausch E; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Cologne, Germany.
Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Brüggemann M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Herling CD; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Blood [Blood] 2021 Apr 22; Vol. 137 (16), pp. 2267-2271.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance.
Autorzy :
Fürstenau M; German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Department I of Internal Medicine, University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.; Cancer Center Cologne Essen (CCCE)-Partner Site Cologne, University of Cologne, 50937 Cologne, Germany.
Eichhorst B; German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Department I of Internal Medicine, University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.; Cancer Center Cologne Essen (CCCE)-Partner Site Cologne, University of Cologne, 50937 Cologne, Germany.
Pokaż więcej
Źródło :
Cancers [Cancers (Basel)] 2021 Mar 16; Vol. 13 (6). Date of Electronic Publication: 2021 Mar 16.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Autorzy :
Cramer P; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Tresckow JV; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Robrecht S; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Bahlo J; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Fürstenau M; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Langerbeins P; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Pflug N; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Al-Sawaf O; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Heinz WJ; University of Würzburg, Medical Center, Medical Clinic II, Würzburg, Germany.
Vehling-Kaiser U; Tagesklinik Landshut, Landshut, Germany.
Dürig J; University Hospital Essen, Department for Hematology, West German Cancer Center, Essen, Germany.
Tausch E; Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany.
Hensel M; Mannheimer Onkologie Praxis, Mannheim, Germany.
Sasse S; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Fink AM; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Fischer K; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Kreuzer KA; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Böttcher S; Department III of Internal Medicine, Rostock University Medical Center, Rostock, Germany.
Ritgen M; Department of Internal Medicine II, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Kneba M; Department of Internal Medicine II, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Wendtner CM; Department of Hematology, Oncology, Immunology, Klinikum Schwabing, Munich, Germany.
Stilgenbauer S; Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany.
Eichhorst B; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Hallek M; University of Cologne, Dept. of Internal Medic University Hospital of Cologne, Germany.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2021 Feb 01; Vol. 106 (2), pp. 543-554. Date of Electronic Publication: 2021 Feb 01.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Adenine/analogs & derivatives ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride ; Humans ; Piperidines ; Treatment Outcome
Czasopismo naukowe
Tytuł :
COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia.
Autorzy :
Langerbeins P; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
Fürstenau M; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
Gruell H; Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Klein F; Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Persigehl T; Department of Radiology, University Hospital, Cologne, Germany.
Rybniker J; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
Seeger-Nukpezah T; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
Kochanek M; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
Hallek M; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
Eichhorst B; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
Koehler P; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne, and University Hospital Cologne, Cologne, Germany.
Böll B; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
Pokaż więcej
Źródło :
European journal of haematology [Eur J Haematol] 2020 Oct; Vol. 105 (4), pp. 508-511. Date of Electronic Publication: 2020 Jul 10.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
COVID-19/*complications
Coinfection/*complications
Leukemia, Lymphocytic, Chronic, B-Cell/*complications
Paramyxoviridae Infections/*complications
Antibodies, Viral/blood ; COVID-19/immunology ; COVID-19/therapy ; Humans ; IgG Deficiency/complications ; IgG Deficiency/immunology ; IgG Deficiency/therapy ; Immunoglobulins, Intravenous/therapeutic use ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Male ; Middle Aged ; Pandemics ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology
Czasopismo naukowe
Tytuł :
COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Autorzy :
Fürstenau M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany. moritz.fuerstenau@uk-koeln.de.
Langerbeins P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
De Silva N; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Robrecht S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
von Tresckow J; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Simon F; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Hohloch K; Department of Internal Medicine, Hematology and Medical Oncology, Kantonsspital Graubünden, Chur, Switzerland.; Department of Hematology and Oncology, University Hospital Göttingen, Göttingen, Germany.
Droogendijk J; Division of Hematology and Oncology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands.
van der Klift M; Division of Hematology and Oncology, Amphia Ziekenhuis Breda, Breda, The Netherlands.
van der Spek E; Department of Internal Medicine, Ziekenhuis Rijnstate, Arnhem, The Netherlands.
Illmer T; BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Germany.
Schöttker B; Hämatologisch-onkologische Schwerpunktpraxis Würzburg, Würzburg, Germany.
Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Wendtner CM; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, German CLL Study Group, Munich Clinic Schwabing, Munich, Germany.
Tausch E; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
Stilgenbauer S; Department of Internal Medicine III, University of Ulm, Ulm, Germany.; Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.
Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Gregor M; Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
Kater AP; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Aug; Vol. 34 (8), pp. 2225-2229. Date of Electronic Publication: 2020 Jun 29.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Betacoronavirus/*isolation & purification
Coronavirus Infections/*transmission
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Pneumonia, Viral/*transmission
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; COVID-19 ; Coronavirus Infections/diagnosis ; Coronavirus Infections/virology ; Female ; Follow-Up Studies ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Leukemia, Lymphocytic, Chronic, B-Cell/virology ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/virology ; Prognosis ; Pyrazoles/administration & dosage ; Pyrimidines/administration & dosage ; Rituximab/administration & dosage ; SARS-CoV-2 ; Sulfonamides/administration & dosage
Czasopismo naukowe
Tytuł :
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.
Autorzy :
Fürstenau M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany. moritz.fuerstenau@uk-koeln.de.
Hopfinger G; Department of Internal Medicine I, Bone Marrow Transplantation, Medical University of Vienna, Vienna, Austria.
Robrecht S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Al-Sawaf O; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Langerbeins P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Cramer P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Tresckow JV; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Maurer C; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Kutsch N; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Hoechstetter M; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany.
Dreyling M; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Lange E; Evangelisches Krankenhaus Hamm, Hamm, Germany.
Kneba M; Department II of Internal Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Stilgenbauer S; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.; Department of Hematology, Oncology and Rheumatology and José Carreras Center for Immuno and Gene Therapy, Saarland University Medical School, Homburg/Saar, Germany.
Döhner H; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Hensel M; Mannheim Oncology Practice, Mannheim, Germany.
Kiehl MG; Department of Internal Medicine, Frankfurt (Oder) General Hospital, Frankfurt/Oder, Germany.
Jaeger U; Department of Medicine I, Clinical Division of Hematology and Hemostaseology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
Wendtner CM; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany.
Goede V; Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.
Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
von Bergwelt-Baildon M; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Theurich S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany. .; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany. .; Gene Center, Cancer- and Immunometabolism Research Group, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Apr; Vol. 34 (4), pp. 1177-1181. Date of Electronic Publication: 2019 Nov 14.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Immunotherapy/*mortality
Leukemia, Lymphocytic, Chronic, B-Cell/*mortality
Obesity/*physiopathology
Adult ; Aged ; Aged, 80 and over ; Bendamustine Hydrochloride/administration & dosage ; Clinical Trials, Phase III as Topic ; Female ; Follow-Up Studies ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Rituximab/administration & dosage ; Sex Factors ; Survival Rate ; Vidarabine/administration & dosage
Raport
Tytuł :
Invasive Aspergillosis in Patients Treated With Ibrutinib.
Autorzy :
Fürstenau M; Department I of Internal Medicine and Centre of Integrated Oncology ABCD, German CLL Study Group, University Hospital Cologne, Cologne, Germany.
Simon F; Department I of Internal Medicine and Centre of Integrated Oncology ABCD, German CLL Study Group, University Hospital Cologne, Cologne, Germany.
Cornely OA; Department I for Internal Medicine, Excellence Centre for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany.; Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Disease (CECAD), University of Cologne, Cologne, Germany.; Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
Hicketier T; Department of Radiology, University Hospital Cologne, Cologne, Germany.
Eichhorst B; Department I of Internal Medicine and Centre of Integrated Oncology ABCD, German CLL Study Group, University Hospital Cologne, Cologne, Germany.
Hallek M; Department I of Internal Medicine and Centre of Integrated Oncology ABCD, German CLL Study Group, University Hospital Cologne, Cologne, Germany.; Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Disease (CECAD), University of Cologne, Cologne, Germany.
Mellinghoff SC; Department I for Internal Medicine, Excellence Centre for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany.; Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Disease (CECAD), University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
HemaSphere [Hemasphere] 2020 Feb 13; Vol. 4 (2), pp. e309. Date of Electronic Publication: 2020 Feb 13 (Print Publication: 2020).
Typ publikacji :
Letter
Opinia redakcyjna
Tytuł :
Relapsed disease and aspects of undetectable MRD and treatment discontinuation.
Autorzy :
Eichhorst B; Department I for Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf; and.
Fürstenau M; Department I for Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf; and.
Hallek M; Department I for Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf; and.; Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2019 Dec 06; Vol. 2019 (1), pp. 482-489.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell*/blood
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Biomarkers, Tumor/*blood
Aged ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Female ; Humans ; Neoplasm, Residual ; Pyrazoles/administration & dosage ; Pyrimidines/administration & dosage ; Recurrence ; Rituximab/administration & dosage ; Sulfonamides/administration & dosage
Czasopismo naukowe
Tytuł :
Sequential and combination treatments with novel agents in chronic lymphocytic leukemia.
Autorzy :
Fürstenau M; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne.
Hallek M; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne.; Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Disease (CECAD), University of Cologne, Cologne, Germany.
Eichhorst B; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne .
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2019 Nov; Vol. 104 (11), pp. 2144-2154. Date of Electronic Publication: 2019 Oct 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Algorithms ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Clinical Trials as Topic ; Combined Modality Therapy ; Disease Management ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Molecular Targeted Therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
Autorzy :
Fürstenau M; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, German CLL Study Group, University Hospital Cologne, Cologne, Germany.
De Silva N; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, German CLL Study Group, University Hospital Cologne, Cologne, Germany.
Eichhorst B; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, German CLL Study Group, University Hospital Cologne, Cologne, Germany.
Hallek M; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, German CLL Study Group, University Hospital Cologne, Cologne, Germany.; Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Disease (CECAD), University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
HemaSphere [Hemasphere] 2019 Aug 09; Vol. 3 (5), pp. e287. Date of Electronic Publication: 2019 Aug 09 (Print Publication: 2019).
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
How to approach CLL in clinical practice.
Autorzy :
Hallek M; Department I of Internal Medicine, University of Cologne.
Fürstenau M; Department I of Internal Medicine, University of Cologne.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2019 Jun; Vol. 37 Suppl 1, pp. 38-42.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell/*mortality
Leukemia, Lymphocytic, Chronic, B-Cell/*therapy
Humans
Czasopismo naukowe
Tytuł :
Post-procedural N-terminal pro-brain natriuretic peptide predicts one-year mortality after transcatheter aortic valve implantation.
Autorzy :
Vale NC; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal. Electronic address: .
Campante Teles R; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal.
Madeira S; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal.
Brito J; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal.
Sousa Almeida M; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal.
Nolasco T; Cardiac Surgery Department, Santa Cruz Hospital, Carnaxide, Portugal.
Abecasis J; Unidade Cardiovascular, HPP Hospital dos Lusíadas, Lisbon, Portugal.
Rodrigues G; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal.
Carmo J; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal.
Furstenau M; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal.
Ribeiras R; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal.
Neves JP; Cardiac Surgery Department, Santa Cruz Hospital, Carnaxide, Portugal.
Mendes M; Cardiology Department, Santa Cruz Hospital, Carnaxide, Portugal.
Pokaż więcej
Źródło :
Revista portuguesa de cardiologia [Rev Port Cardiol (Engl Ed)] 2018 Jan; Vol. 37 (1), pp. 67-73. Date of Electronic Publication: 2018 Jan 06.
Typ publikacji :
Journal Article
MeSH Terms :
Natriuretic Peptide, Brain/*blood
Peptide Fragments/*blood
Transcatheter Aortic Valve Replacement/*mortality
Aged, 80 and over ; Female ; Humans ; Male ; Postoperative Period ; Predictive Value of Tests ; Prognosis ; Retrospective Studies ; Time Factors
Czasopismo naukowe
Tytuł :
Efficacy of mefloquine intermittent preventive treatment in pregnancy against Schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial.
Autorzy :
Basra A; Centre de Recherches Médicales de Lambaréné, Université des Sciences de la Santé, Libreville, Gabon.
Mombo-Ngoma G
Melser MC
Diop DA
Würbel H
Mackanga JR
Fürstenau M
Zoleko RM
Adegnika AA
Gonzalez R
Menendez C
Kremsner PG
Ramharter M
Pokaż więcej
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2013 Mar; Vol. 56 (6), pp. e68-75. Date of Electronic Publication: 2012 Nov 21.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anthelmintics/*administration & dosage
Chemoprevention/*methods
Mefloquine/*administration & dosage
Pregnancy Complications, Parasitic/*prevention & control
Schistosomiasis haematobia/*prevention & control
Adult ; Animals ; Drug Combinations ; Feces/parasitology ; Female ; Gabon ; Humans ; Parasite Egg Count ; Pregnancy ; Pyrimethamine/administration & dosage ; Rural Population ; Schistosoma haematobium/isolation & purification ; Single-Blind Method ; Sulfadoxine/administration & dosage ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Regulation of calcium sparks and spontaneous transient outward currents by RyR3 in arterial vascular smooth muscle cells.
Autorzy :
Löhn M; HELIOS Klinikum-Berlin, Franz Volhard Clinic and Max Delbrück Center for Molecular Medicine, Medical Faculty of the Charité, Humboldt University Berlin, Germany.
Jessner W
Fürstenau M
Wellner M
Sorrentino V
Haller H
Luft FC
Gollasch M
Pokaż więcej
Źródło :
Circulation research [Circ Res] 2001 Nov 23; Vol. 89 (11), pp. 1051-7.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Calcium Signaling*
Arteries/*cytology
Calcium/*metabolism
Muscle, Smooth, Vascular/*physiology
Potassium Channels, Calcium-Activated/*physiology
Ryanodine Receptor Calcium Release Channel/*physiology
Animals ; Cells, Cultured ; Cerebral Arteries/cytology ; Cerebral Arteries/physiology ; Electric Conductivity ; Ion Transport ; Mice ; Mice, Knockout ; Models, Cardiovascular ; Protein Isoforms/biosynthesis ; Protein Isoforms/genetics ; RNA, Messenger/biosynthesis ; Ryanodine Receptor Calcium Release Channel/genetics ; Vasoconstriction
Czasopismo naukowe
Tytuł :
Ignition of calcium sparks in arterial and cardiac muscle through caveolae.
Autorzy :
Löhn M; Franz Volhard Clinic and Max Delbrück Center for Molecular Medicine, Charité University Hospitals, Humboldt University of Berlin, Germany.
Fürstenau M
Sagach V
Elger M
Schulze W
Luft FC
Haller H
Gollasch M
Pokaż więcej
Źródło :
Circulation research [Circ Res] 2000 Nov 24; Vol. 87 (11), pp. 1034-9.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
beta-Cyclodextrins*
Calcium Signaling/*physiology
Caveolae/*metabolism
Muscle, Smooth, Vascular/*metabolism
Myocardium/*metabolism
Aging/metabolism ; Animals ; Animals, Newborn ; Caffeine/pharmacology ; Calcium/metabolism ; Calcium Channels, L-Type/drug effects ; Calcium Channels, L-Type/metabolism ; Calcium Signaling/drug effects ; Caveolae/ultrastructure ; Cell Membrane/metabolism ; Cell Membrane/ultrastructure ; Cell Separation ; Cells, Cultured ; Cholesterol/metabolism ; Cyclodextrins/pharmacology ; Dose-Response Relationship, Drug ; Muscle, Smooth, Vascular/cytology ; Myocardium/cytology ; Patch-Clamp Techniques ; Phosphodiesterase Inhibitors/pharmacology ; Rats ; Rats, Sprague-Dawley ; Ryanodine/pharmacology ; Sarcoplasmic Reticulum/metabolism
Czasopismo naukowe
Tytuł :
[Ulcer anamnesis and gastroduodenoscopic findings--a contribution to the symptomatology of gastroduodenal ulcers].
Autorzy :
Kratzsch KH
Fürstenau M
Zimmermann S
Pokaż więcej
Transliterated Title :
Ulkusanamnese und gastroduodenoskopischer Befund--ein Beitrag zur Symptomatologie des gastroduodenalen Ulkus.
Źródło :
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete [Z Gesamte Inn Med] 1979 Sep 15; Vol. 34 (18), pp. 530-4.
Typ publikacji :
English Abstract; Journal Article
MeSH Terms :
Duodenum/*pathology
Peptic Ulcer/*pathology
Diagnosis, Differential ; Endoscopy ; Female ; Fiber Optic Technology ; Gastroscopy ; Humans ; Intestinal Mucosa/pathology ; Male ; Peptic Ulcer/diagnosis ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
[Humoral immune reaction in chronic liver diseases].
Autorzy :
Kratzsch KH
Zimmermann S
Morenz J
Fürstenau M
Zugehör M
Claus B
Lewicki I
Pokaż więcej
Transliterated Title :
Humorale Immunreaktionen bei chronischen Lebererkrankungen
Źródło :
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete [Z Gesamte Inn Med] 1976 Jul 15; Vol. 31 (14), pp. 533-5.
Typ publikacji :
English Abstract; Journal Article
MeSH Terms :
Liver Diseases/*immunology
Adult ; Antibodies/analysis ; Antibody Formation ; Chronic Disease ; Female ; Hepatitis/immunology ; Humans ; Immunoglobulins/isolation & purification ; Liver Cirrhosis/immunology ; Male ; Middle Aged ; Muscle, Smooth/immunology
Czasopismo naukowe
Tytuł :
[X-ray examinations of the stomach--comparison of the findings with gastroscopy].
Autorzy :
Kücken G
Fürstenau M
Pokaż więcej
Transliterated Title :
Röntgenuntersuchungen des Magens--Vergleich erhobener Befunde mit der Gastroskopie.
Źródło :
Radiologia diagnostica [Radiol Diagn (Berl)] 1986; Vol. 27 (6), pp. 753-60.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Stomach Diseases/*diagnosis
Gastroscopy ; Humans ; Radiography ; Stomach Diseases/diagnostic imaging
Czasopismo naukowe
Tytuł :
[The value of fiber gastroscopy and targeted gastrobiopsy in the diagnosis of stomach ulcers and tumors].
Autorzy :
Kratzsch KH
Kubisch H
Fürstenau M
Winkelvoss H
Büttner W
Pokaż więcej
Transliterated Title :
Zur Aussagefähigkeit der Fibergastroskopie und gezielten Gastrobiopsie in der Diagnostik von Ulzera und Tumoren des Magens.
Źródło :
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete [Z Gesamte Inn Med] 1979 Oct 01; Vol. 34 (19), pp. 265-7.
Typ publikacji :
English Abstract; Journal Article
MeSH Terms :
Stomach Neoplasms/*diagnosis
Stomach Ulcer/*diagnosis
Biopsy ; Diagnostic Errors ; False Negative Reactions ; Fiber Optic Technology ; Gastroscopy ; Humans
Czasopismo naukowe
Tytuł :
[Fiber-optic endoscopy demonstration, incidence and clinical significance of intestinal lymphangiectasis].
Autorzy :
Fürstenau M
Kratzsch KH
Zimmermann S
Büttner W
Pokaż więcej
Transliterated Title :
Fiberendoskopischer Nachweis, Häufigkeit und klinische Bedeutung der intestinalen Lymphangiektasie.
Źródło :
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete [Z Gesamte Inn Med] 1977 Nov 15; Vol. 32 (22), pp. 638-40.
Typ publikacji :
Case Reports; English Abstract; Journal Article
MeSH Terms :
Endoscopy/*methods
Lymphangiectasis, Intestinal/*diagnosis
Protein-Losing Enteropathies/*diagnosis
Biopsy/methods ; Fiber Optic Technology ; Humans ; Lymphangiectasis, Intestinal/etiology ; Lymphangiectasis, Intestinal/pathology ; Male ; Middle Aged ; Optical Fibers ; Stomach Neoplasms/complications
Czasopismo naukowe
Tytuł :
[Therapeutic aspects of endoscopic polypectomy].
Autorzy :
Kratzsch KH
Stibenz J
Fürstenau M
Winkelvoss H
Büttner W
Jacobasch KH
Gütz HJ
Irro F
Pokaż więcej
Transliterated Title :
Therapeutische Aspekte der endoskopischen Polypektomie.
Źródło :
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete [Z Gesamte Inn Med] 1980 Feb 15; Vol. 35 (4), pp. 173-5.
Typ publikacji :
English Abstract; Journal Article
MeSH Terms :
Endoscopy*
Colonic Neoplasms/*surgery
Intestinal Neoplasms/*surgery
Intestinal Polyps/*surgery
Polyps/*surgery
Stomach Neoplasms/*surgery
Adenocarcinoma/surgery ; Adenoma/surgery ; Carcinoid Tumor/surgery ; Carcinoma/surgery ; Gastrointestinal Neoplasms/diagnosis ; Histiocytoma, Benign Fibrous/surgery ; Humans ; Hyperplasia/surgery ; Neoplasm Invasiveness ; Neurofibroma/surgery ; Precancerous Conditions/surgery
Czasopismo naukowe
    Wyświetlanie 1-51 z 51

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies